Format

Send to:

Choose Destination
See comment in PubMed Commons below
South Med J. 2006 Feb;99(2):123-31.

Cost-effectiveness strategies to treat osteoporosis in elderly women.

Author information

  • 1Department of Medicine, West Virginia University School of Medicine, Charleston 25304, USA. apfister@hcs.wvu.edu

Abstract

BACKGROUND:

Comparing the cost-effectiveness of various antiosteoporotic drugs has not been defined.

METHODS:

We determined the cost-effectiveness of calcitonin, raloxifene, bisphosphates and PTH in a base-case cohort of women aged 65 or older with osteoporosis. After bone densitometry, women were stratified into groups of treatment or no treatment. Our outcome goal was a value of dollars 100,000 or less per quality-adjusted life years (QALY). A sensitivity analysis varied nonvertebral fracture reduction and compliance between the two most effective strategies to test various cost per QALY thresholds.

RESULTS:

Bisphosphonates displayed the most favorable incremental cost saving and prevented more fractures in our base-case analysis. In a sensitivity analysis, virtually all values of bisphosphonates were under dollars 100,000 per QALY and parathyroid hormone (PTH) was between dollars 100,000 and dollars 200,000 per QALY.

CONCLUSIONS:

Only bisphosphonates are cost-effective for fracture prevention in osteoporotic women aged 65 or older and this economic advantage is also maintained in subsets who have a lower relative risk of future fracture.

PMID:
16509549
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Southern Medical Association
    Loading ...
    Write to the Help Desk